Expression and significance of NOD-like receptor family protein 3 in middle-aged and elderly patients with endometrioid adenocarcinoma

doi:10.3877/cma.j.issn.2095-8757.2020.04.003

Abstract

Abstract:

Objective

To investigate the expression and clinical significance of NOD-like receptor protein 3 (NLRP3) in middle-aged and elderly patients with endometrioid adenocarcinoma.

Methods

13 patients with endometrioid adenocarcinoma and underwent surgical resection admitted to Zhejiang Hospital and Zhejiang Cancer Hospital from January 2017 to December 2019 were selected. At the same time, 12 patients with uterine prolapse who underwent total hysterectomy were selected. The expression levels of NLRP3 mRNA and protein were detected by real-time PCR, Western blot and immunohistochemistry. The effects of NLRP3 on proliferation, invasion and migration of endometrial adenocarcinoma cell lines Ishikawa and HEC-1A were observed in vitro. T test was used to compare the measurement data between the groups.

Results

Immunohistochemical analysis showed that the expression level of NLRP3 in endometrioid adenocarcinoma tissues was significantly higher than that in normal endometrium tissues, and increased with the increase of FIGO stage and pathological grade. PCR results showed that the expression levels of NLRP3 mRNA and NLRP3 protein in the endometrioid adenocarcinoma tissue were significantly higher than those in the normal endometrial tissue (t=3.769, 4.316; P < 0.05). Western blot results showed that the expression of NLRP3 protein in endometrioid adenocarcinoma tissues was significantly higher than that in normal endometrium tissues. Cell assay results showed that NLRP3 mRNA and NLRP3 protein were expressed in both Ishikawa cells and HEC-1a cells, and the expression levels of NLRP3 mRNA and NLRP3 protein in HEC-1A cells were significantly higher than those in Ishikawa cells (t =2.373, 2.559; P < 0.05); after silencing NLRP3 of Ishikawa cells and HEC-1A cells with siRNA, the proliferation ability of the cells was significantly limited from the third day, and continued to the seventh day after the end of cell proliferation experiment; transwell assay showed that the number of migration and invasion of Ishikawa cells and HEC-1a cells decreased significantly after NLRP3 silencing (t=7.343, 6.571, 3.859, 3.289; P < 0.05).

Conclusion

The expression of NLRP3 is closely related to the pathology, proliferation, invasion and migration of endometrioid adenocarcinoma.

Key words: Endometrioid adenocarcinoma, NOD-like receptor protein 3, Inflammation, Proliferation, Migration, Invasion

Jinhong Zhou, Shumei Zeng, Lingqin Zhao, Xianying Cheng, Wenjun Li. Expression and significance of NOD-like receptor family protein 3 in middle-aged and elderly patients with endometrioid adenocarcinoma[J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2020, 07(04): 16-20.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlnbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8757.2020.04.003

https://zhlnbyjdzzz.cma-cmc.com.cn/EN/Y2020/V07/I04/16

Figures/Tables 10

References 27

[1]	Doll K, Winn A. Assessing endometrial cancer risk among US women: long-term trends using hysterectomy-adjusted analysis[J]. Am J Obstet Gynecol, 2019, 221(4):311-318.
[2]	Rebecca LS, Kimberly DM, Ahmedin J. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1):7-30.
[3]	Savant S, Sriramkumar S, O'Hagan H. The role of inflammation and inflammatory mediators in the development, progression, metastasis, and chemoresistance of epithelial ovarian cancer[J]. Cancers (Basel), 2018, 10(8):E251.
[4]	Murata M. Inflammation and cancer[J]. Environ Health Prev Med, 2018, 23(1):50.
[5]	Saxena M, Yeretssian G. NOD-like receptors: Master regulators of inflammation and cancer[J]. Front Immunol, 2014, 5:327.
[6]	Sutterwala FS, Haasken S, Cassel SL. Mechanism of NLRP3 inflammasome activation[J]. Ann N Y Acad Sci, 2014, 1319(1):82-95.
[7]	Menu P, Vince JE. The NLRP3 inflammasome in health and disease: the good, the bad and the ugly[J]. Clin Exp Immunol, 2011, 166(1):1-15.
[8]	Wieser V, Abdel Azim S, Sprung S, et al. TNFα signalling predicts poor prognosis of patients with endometrial cancer[J]. Carcinogenesis, 2020, 41(8):1065-1073.
[9]	Ye Y, Wang X, Jeschke U, et al. COX-2-PGE-EPs in gynecological cancers[J]. Arch Gynecol Obstet, 2020, 301(6):1365-1375.
[10]	Heidari F, Rabizadeh S, Mansournia M, et al. Inflammatory, oxidative stress and anti-oxidative markers in patients with endometrial carcinoma and diabetes[J]. Cytokine, 2019, 120:186-190.
[11]	Che Q, Xiao X, Xu J, et al. 17β-Estradiol promotes endometrial cancer proliferation and invasion through IL-6 pathway[J]. Endoc Connect, 2019, 8(7):961-968.
[12]	Che Q, Liu B, Wang F, et al. Interleukin 6 promotes endometrial cancer growth through an autocrine feedback loop involving ERK-NF-κB signaling pathway[J]. Biochem Biophys Res Commun, 2014, 446(1):167-172.
[13]	蒋丹露，刘阳阳，孙如愚，等.NLRP3炎症小体介导的炎症相关疾病研究进展[J].生命科学，2017，29（9）：88-97.
[14]	Virginie P. The multifaceted roles of inflammasome proteins in cancer[J]. Curr Opin Oncol, 2017, 29(1):35-40.
[15]	Paul MR, Jean GM, Tom T, et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial[J]. Lancet, 2017, 390(10105):1833-1842.
[16]	Ajduković J. Colorectal cancer and NLRP-current knowledge[J]. Immunome Res, 2018, doi:10.4172/1745-7580.1000153.
[17]	Deswaerte V, Nguyen P, West A, et al. Inflammasome adaptor ASC suppresses apoptosis of gastric cancer cells by an IL 18-mediated inflammation-independent mechanism[J]. Cancer Res, 2018, 78(5):1293-1307.
[18]	Ahmad I, Muneer KM, Tamimi IA, et al. Thymoquinone suppresses metastasis of melanoma cells by inhibition of NLRP3 inflammasome[J]. Toxicol Appl Pharmacol, 2013, 270(1):70-76.
[19]	Modugno F, Ness RB, Chen C, et al. Inflammation and endometrial cancer: A hypothesis[J]. Cancer Epidemiol Biomarkers Prev, 2005, 14(12):2840-2847.
[20]	Ohno S, Kinoshita T, Ohno Y. Expression of NLRP7 (PYPAF3, NALP7) protein in endometrial cancer tissues[J]. Anticancer Res, 2008, 28(4C):2493-2497.
[21]	Amin J, Boche D, Rakic S. What do we know about the inflammasome in humans[J]? Brain Pathology, 2017, 27(2):192-204.
[22]	Mausita K, Michael K, Hesham AM, et al. Neutrophil IL-1β processing induced by pneumolysin is mediated by the NLRP3/ASC inflammasome and caspase-1 activation and is dependent on K⁺ efflux[J]. J Immunology, 2015, 194(4):1763-1775.
[23]	Shen HH, Yang YX, Meng X, et al. NLRP3: A promising therapeutic target for autoimmune diseases[J]. Autoimmun Rev, 2018, 17(7):694-702.
[24]	Benjamin W, Rüdiger P, Sarah D, et al. S1PR1 on tumor-associated macrophages promotes lymphangiogenesis and metastasis via NLRP3/IL-1β[J]. J Exp Med, 2017, 214(9):2695-2713.
[25]	许燕，卢顺麟.PGE2通过EP4受体上调Hela细胞中NLRP3的表达[J].中国医师杂志，2018，20（7）：1042-1043.
[26]	Wei Q, Mu K, Li T, et al. Deregulation of the NLRP3 inflammasome in hepatic parenchymal cells during liver cancer progression[J]. Lab Invest, 2014, 94(1):52-62.
[27]	刘延刚，陈永春，宗英，等.NLRP3炎症小体的活化及调控机制[J].第二军医大学学报，2016，37（7）：868-872.

组别	例数	NLRP3 mRNA	NLRP3蛋白
子宫内膜样腺癌组织	13	1.02±0.21	1.32±0.25
正常子宫内膜组织	12	0.18±0.06	0.20±0.09
t值		3.769	4.316
P值		<0.01	<0.01

组别	例数	NLRP3 mRNA	NLRP3蛋白
子宫内膜样腺癌组织	13	1.02±0.21	1.32±0.25
正常子宫内膜组织	12	0.18±0.06	0.20±0.09
t值		3.769	4.316
P值		<0.01	<0.01

组别	NLRP3 mRNA	NLRP3蛋白
ishikawa细胞	0.65±0.07	0.53±0.06
HEC-1A细胞	0.91±0.15	0.86±0.12
t值	2.373	2.559
P值	<0.05	<0.05

组别	NLRP3 mRNA	NLRP3蛋白
ishikawa细胞	0.65±0.07	0.53±0.06
HEC-1A细胞	0.91±0.15	0.86±0.12
t值	2.373	2.559
P值	<0.05	<0.05

组别	细胞迁移		细胞侵袭
组别	ishikawa细胞	HEC-1A细胞	ishikawa细胞	HEC-1A细胞
对照siRNA	100.0±5.6	100.0±4.1	100.0±7.8	100.0±7.1
NLRP3 siRNA	45.0±4.9	56.0±5.7	64.0±5.3	67.0±6.9
t值	7.343	6.571	3.859	3.289
P值	<0.01	<0.01	<0.01	=0.01

Please choose a citation manager

Content to export